We previously demonstrated the simultaneous induction of urokinase-type plasminogen activator and interleukin-8, a CXC chemokine, in doxorubicin-treated human NCI-H69 small cell lung cancer cells in which extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase might be involved. NCI-H69 cells expressed one of the receptor tyrosine kinases, c-Kit, and STI571 inhibited the cell growth and stem cell factor-induced phosphorylation of c-Kit. We therefore investigated the effects of STI571 on the expression of urokinase-type plasminogen activator and interleukin-8 in NCI-H69 cells. Microarray analysis revealed the gene induction of not only urokinase-type plasminogen activator and interleukin-8, but also early growth response-1 in STI571-treated cells. Treatment with STI571 resulted in the induction of phosphorylation of all three mitogen-activated protein kinases, such as extracellular signal-regulated kinase 1/2, p38 mitogen-activated protein kinase and stress-activated protein kinase/c-jun N-terminal protein kinase. U0126, an inhibitor against extracellular signal-regulated kinase 1/2, however, only inhibited the STI571-induced interleukin-8 accumulation. Urokinase-type plasminogen activator and interleukin-8 are important biological factors in tumor cell regulation; STI571 may therefore influence many aspects of tumor cell biology through inducing urokinase-type plasminogen activator and interleukin-8, in which the induction of early growth response-1 expression and extracellular signal-regulated kinase 1/2 phosphorylation might be involved. Blood Coagul Fibrinolysis 18:425-433 ß 2007 Lippincott Williams & Wilkins. Blood Coagulation and Fibrinolysis 2007, 18:425-433 Keywords: early growth response-1, interleukin-8, mitogen-activated protein kinase, small cell lung cancer, STI571, urokinase-type plasminogen activator
We previously demonstrated the simultaneous induction of urokinase-type plasminogen activator and interleukin-8, a CXC chemokine, in doxorubicin-treated human NCI-H69 small cell lung cancer cells in which extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase might be involved. NCI-H69 cells expressed one of the receptor tyrosine kinases, c-Kit, and STI571 inhibited the cell growth and stem cell factor-induced phosphorylation of c-Kit. We therefore investigated the effects of STI571 on the expression of urokinase-type plasminogen activator and interleukin-8 in NCI-H69 cells. Microarray analysis revealed the gene induction of not only urokinase-type plasminogen activator and interleukin-8, but also early growth response-1 in STI571-treated cells. Treatment with STI571 resulted in the induction of phosphorylation of all three mitogen-activated protein kinases, such as extracellular signal-regulated kinase 1/2, p38 mitogen-activated protein kinase and stress-activated protein kinase/c-jun N-terminal protein kinase. U0126, an inhibitor against extracellular signal-regulated kinase 1/2, however, only inhibited the STI571-induced interleukin-8 accumulation. Urokinase-type plasminogen activator and interleukin-8 are important biological factors in tumor cell regulation; STI571 may therefore influence many aspects of tumor cell biology through inducing urokinase-type plasminogen activator and interleukin-8, in which the induction of early growth response-1 expression and extracellular signal-regulated kinase 1/2 phosphorylation might be involved. Introduction A 145-kDa transmembrane protein, c-Kit, is one of the type III receptor tyrosine kinase family [1] . Steel factor, which is also called stem cell factor (SCF), is the cognate ligand for c-Kit. The binding of SCF to c-Kit results in receptor homodimerization, the activation of c-Kit tyrosine kinase activity, and the resultant phosphorylation of a variety of substrates involved in the intracellular signal transductions that control cellular activities, such as proliferation, apoptosis and differentiation [2] . The coexpression of both c-Kit and SCF has been reported in a variety of human malignancies, and these observations suggest the possibility of an autocrine or paracrine growth loop involving the SCF/c-Kit system in these malignancies [3] [4] [5] [6] [7] [8] . Similarly, it is known that approximately 70% of small cell lung cancer (SCLC) cells express both SCF and c-Kit [9, 10] , and these facts have led to efforts to block the SCF/c-Kit mediated signaling for a new approach of SCLC treatment.
A selective tyrosine kinase inhibitor, STI571 (imatinib mesylate), was originally developed as an ATP competitive inhibitor of the Abl tyrosine kinase [11] . STI571 inhibited not only the kinase activity of Abl, but also the kinase activity of c-Kit and platelet-derived growth factor receptors a and b [12] . In chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, this tyrosine kinase inhibition was directed against BCR/ABL, a constitutively activated tyrosine kinase that is the product of the Philadelphia chromosome [11] . STI571 induced complete hematological remissions in almost all chronic phase CML patients [13] , and it had substantial inhibitory activity on the tumor cell growth of the blast crisis of CML patients and Philadelphia-positive acute lymphoblastic leukemia patients [14] . Furthermore, the results of the safety and efficacy of STI571 on the metastatic gastrointestinal stromal tumor patients, in most cases expressing a mutant and/or activated c-Kit, provided evidence for the role of c-Kit in gastrointestinal stromal tumor, and demonstrated the potential of this drug in the management of this disease [15] . Various studies have shown recently that STI571 inhibited the growth of SCLC cells in vitro via the inactivation of the tyrosine kinase activity associated with the SCF/c-Kit system [16, 17] . The anticancer activity of STI571 on SCLC patients was therefore expected. Monotherapy with STI571, however, showed little anticancer effect in patients with SCLC who were in a primary extensive stage or in a sensitive relapse [18] . An alternative approach, such as the combination of STI571 and other tyrosine kinase inhibitors against different growth factors or other anticancer agents, was therefore needed [19] . Doxorubicin is one of the most widely used anticancer drugs for the treatment of SCLC, and we therefore studied the combination effect of doxorubicin and STI571 on the growth of NCI-H69 SCLC cells. Preliminary experiments revealed that STI571 did not show any strong additive or synergistic effects on the doxorubicininduced inhibition of cell growth, but, interestingly, STI571 alone significantly inhibited cell growth and induced urokinase-type plasminogen activator (uPA) expression in the cells.
We previously reported the induction of uPA, interleukin-8 (IL-8), monocyte chemoattractant protein-1, and tumor necrosis factor-a in NCI-H69 cells with sublethal concentrations of doxorubicin [20] [21] [22] . We then examined whether STI571 could induce the expression of these genes in NCI-H69 cells. As expected, stimulation with STI571 resulted in the expression of uPA and IL-8 genes, and therefore we performed microarray analysis to detect a series of genes that were induced by stimulation with STI571 in the cells. Here, we demonstrated that STI571 not only induced uPA and IL-8, but also an early growth response-1 (Egr-1) in SCLC cells in which a member of the mitogen-activated protein kinase (MAPK) family, extracellular signal-regulated kinase (ERK), was involved.
Materials and methods
Cell culture and reagents NCI-H69 cells obtained from ATCC (Rockville, Maryland, USA) were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (Sigma, St Louis, Missouri, USA), 100 U/ml penicillin, and 100 mg/ml streptomycin. STI571 [chemical structure: 4-(4-methylpiperazin-1-ylmethyl)-N-[4methyl-3-(4-pyridin-3-ylpyrimidin-2-ylamino)phenyl]; molecular weight, 589.72] was kindly provided by Novartis Pharma AG (Basel, Switzerland), and it was prepared as a 10 mmol/l stock solution in distilled sterile water. In the stimulating experiment with STI571, cells were washed once with phosphate-buffered saline, resuspended in serum-free RPMI-1640 (at approximately 1 Â 10 6 /ml) and cultured with or without STI571. After 24 h stimulation, 20 ml conditioned medium was transferred to a 96-well plate containing 80 ml RPMI-1640 and 10 ml colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyl tertrazolium bromide (MTT) solution in each well. Cell growth was estimated by the MTT assay for mitochondrial dehydrogenase enzyme activity, as described by Mosmann [23] . The correction curve between cell numbers obtained by the trypan blue dye exclusion method under bright-field microscopy and the amount of blue MTT formazan generated was used to estimate the cell numbers, and the results were expressed as the cell density (ratio to untreated controls). The uPA activities in the cultured medium were measured by S-2444 (Chromogenix, Milano, Italy), a chromogenic substrate for uPA. Fifty microliters of cultured medium was transferred to a 96-well plate and 25 ml of 2 mmol/l S-2444 (final concentration, 0.67 mmol/l) was added to each well, and then incubated for 20 min at 378C. The uPA activities were determined by the difference in absorbance per second at 405 nm between the activated and the original substrate using a photometer. Next, we also measured the uPA activities using a plasminogen-containing fibrin plate (fibrin zymography) as previously described [24] . IL-8 and plasminogen activator inhibitor type-1 (PAI-1) antigen levels in the cultured medium were measured using a quantitative enzymelinked immunosorbent assay (ELISA) kit for IL-8 (Immunotech, Marseille, France) and a human PAI-1 ELISA kit (Assaypro, St Charles, Missouri, USA), respectively.
A specific MAPK kinase (MEK) 1/2 inhibitor U0126, purchased from Cell Signaling Technology (Beverly, Massachusetts, USA), and its inactive analog U0124 (Calbiochem, San Diego, California, USA) were dissolved in dimethyl sulphoxide (DMSO). Also, the p38 MAPK inhibitor SB202190 (Calbiochem), and its inactive analog SB202474 (Calbiochem), were dissolved in DMSO. Stress-activated protein kinase/c-jun N-terminal protein kinase (SAPK/JNK) inhibitor JNKI-1 (Calbiochem), and its negative control JNKI-1 NC (Calbiochem), were dissolved in distilled sterile water. Stock solutions were then diluted in RPMI-1640 to achieve the designated final concentrations. In all cases, the final concentrations of DMSO were less than 0.1%, and less than 0.1% of DMSO did not affect the growth of NCI-H69 cells.
Western blot analysis NCI-H69 cells (approximately 5 Â 10 6 cells) harvested after treatment were washed with phosphate-buffered saline and kept in 500 ml cell lysis buffer containing 20 mmol/l Tris (pH 7.5), 150 mmol/l NaCl, 1 mmol/l ethylenediamine tetraacetic acid, 1 mmol/l ethyleneglycolbis-(b-aminoethylether)-N,N,N 0 ,N 0 -tetraacetic acid, 1% Triton X-100, 2.5 mmol/l sodium pyrophosphate, 1 mmol/l b-glycerophophate, 1 mmol/l Na 3 VO 4 , 1 mg/ml leupeptin and 1 mmol/l phenylmethanesulfonyl fluoride on ice for 5 min. Cells were then sonicated four times for 5 s each on ice, and centrifuged at 10 000 Â g for 10 min at 48C. The protein concentration in the supernatants was quantified using protein assay reagent (Bio-Rad Laboratories, Hercules, California, USA). The protein concentration of each sample was corrected with the above cell lysis buffer and 14 ml (almost 20 mg protein) of the sample solution was mixed with 7 ml of 3 Â sodium dodecyl sulfate (SDS) sample buffer [1 Â buffer ¼ 62.5 mmol/l Tris-HCl (pH 6.8), 2% SDS, 10% glycerol, 50 mmol/l dithiothreitol], boiled for 5 min at 958C, and then centrifuged. Twenty microliters of the samples were subjected to SDS-polyacrylamide gel electrophoresis, and after electrophoresis the gels were transferred to the polyvinylidene difluoride membrane. The membrane was kept in Tris-buffered saline with 0.1% Tween-20 (TBS/T) containing 5% skim milk and then washed three times with TBS/T. The membrane was incubated with primary antibody in TBS/T containing 5% bovine serum albumin with gentle agitation overnight at 48C. The primary antibodies used in this manuscript were as follows: rabbit polyclonal antibodies against phospho-c-Kit, c-Kit, phospho-ERK1/2, phospho-p38 MAPK, phospho-SAPK/JNK (all from Cell Signaling Technology) and mouse monoclonal antibodies against ERK1, ERK2, p38 MAPK and c-Jun (all from BD Transduction Laboratories, San Diego, California, USA). Equal loading was verified by immunodetecting the MAPK protein itself. The membrane was washed three times with TBS/T, then reacted with a horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (Cell Signaling Technology) or a sheep anti-mouse secondary antibody (Amersham Life Science, Arlington Heights, Illinois, USA), and visualized using ECL plus western blotting detection reagents (Amersham Biosciences UK Limited, Little Chalfont, UK).
Northern blot analysis
Total RNA was isolated from cells using the acid guanidinium thiocyanate-phenol-chloroform method, and 10 mg total RNA was subjected to northern blot analysis as described by Sambrook et al. [25] . A cDNA probe for uPA was labeled with 32 P-dCTP with a random-primed DNA-labeling technique. mRNA levels were quantitated by counting the radioactivity using a BAS 2000 imaging analyzer (Fuji-film, Tokyo, Japan); as a control for the difference in RNA sample loading, filters were rehybridized with a radiolabeled b-actin cDNA probe.
Reverse transcriptase-polymerase chain reaction
Reverse transcriptase was performed with Superscript II reverse transcriptase (Invitrogen, Carlsbad, California, USA) using 2 mg total RNA as the template according to the manufacturer's instructions. cDNA was synthesized in 20 ml reaction mixtures using oligo(dT) primers. Polymerase chain reaction (PCR) amplification was performed in 1 m of cDNA using gene-specific primers. The sequences of sense and antisense primers for IL-8 were 5 0 -TTGGCAGCCTTCCTGATTTC-3 0 and 5 0 -AACTTCTCCACAACCCTCTGCA-3 0 [26] . The sequences of sense and antisense primers for Egr-1 were 5 0 -TCACCTATACTGGCCGCTTT-3 0 and 5 0 -TGAGTGGCAAAGGCCTTAAT-3 0 [27] . The sequences of sense and antisense primers for GAPDH were 5 0 -CGGATTTGGTCGTATTGG-3 0 and 5 0 -AGATGGTGATGGGATTTC-3 0 [28] . The PCR for IL-8 was performed with 30 cycles of a heat-denaturing step at 948C for 1 min, a primer annealing step at 558C for 30 s, and a strand elongation step at 728C for 1 min. The PCR for Egr-1 was performed with 30 cycles of a heat-denaturing step at 948C for 1 min, a primer annealing step at 618C for 30 s, and a strand elongation step at 728C for 1 min. The PCR for GAPDH was performed with 30 cycles of a heat-denaturing step at 948C for 1 min, a primer annealing step at 508C for 30 s, and a strand elongation step at 728C for 1 min. The PCR products (10 ml) were electrophoresed on 1.5% (for Egr-1) or 2.0% (for IL-8 and GAPDH) agarose gel containing 0.5 mg/ml ethidium bromide. Loading was equalized to the internal control mRNA (GAPDH) to give equivalent signals. Gels were illuminated with ultraviolet light and photographed with a DC290 camera (Kodak, Tokyo, Japan), and were then visualized using a Kodak 1D 3.5.4 software system.
RNase protection assay
Specific detection for mRNA of the chemokine family was performed using the hCK-5 Multi-probe Template set (RiboQuant; Pharmingen, San Diego, California, USA), which contains templates for Ltn, RANTES, IP-10, MIP-1a, MIP-1b, monocyte chemoattractant protein-1, IL-8 and I-309, in addition to the two housekeeping gene products, L32 and GAPDH. In brief, antisense RNA probes were generated from the DNA templates included in the above assay kit using T7 DNA-dependent RNA polymerase in the presence of [a-32 P]UTP (specific activity, 3000 Ci/mmol; ICN, Irvine, California, USA). Labeled probes were hybridized with total RNA (10 mg) overnight at 568C. Unhybridized RNA was digested with ribonuclease (RNase) according to PharMingen's instruction manual. RNase-protected probes were resolved on a 5% denaturing polyacrylamide gel. The gel was dried and visualized using a BAS 2000 imaging analyzer (Fuji-film).
Microarray analysis
To identify the cancer-related and cytokine-related genes whose expressions were affected by the stimulation with STI571 in NCI-H69 cells, we performed microarray analysis using the IntelliGene II Human CHIP 1 (Takara BIO, Otsu, Japan), immobilized with 3893 cDNA fragments of human identified genes, which included 979 kinds of cancer-related and cytokinerelated genes spotted on 12 separate glass plates. Briefly, NCI-H69 cells were cultured in serum-free RPMI-1640 culture medium in the absence or presence of 20 mmol/l STI571 for 2 h. Total RNA was extracted using the method described above and then, by passing through an oligo(dT) column (Oligotex-dt30<super>; Takara Shuzo, Kyoto, Japan), mRNA was further purified. A fluorescent probe was synthesized by incorporating Cy3-dUTP or Cy5-dUTP (Amersham Life Science) using 2 mg above mRNA as a template and reverse transcriptase. As an internal control, 50 pg lambda A (Takara Shuzo) was added to the reaction mixture. Cy3-labeled and Cy5-labeled probes were prepared with mRNA isolated from the control cells and STI571-treated cells, respectively; both were mixed in the reaction buffer [6 Â saline sodium citrate (SSC) (1 Â buffer ¼ 150 mmol/l NaCl, 15 mmol/l sodium citrate, pH 7.0)], 0.2% SDS, 5 Â Denhardt's solution, carrier DNA). The mixture was hybridized to the cDNA CHIP at 658C for 14 h. The CHIP was washed three times with 2 Â SSC and 0.2% SDS solution at 558C for 5 min and then washed with 0.05 Â SSC at room temperature. The hybridized CHIP was visualized and quantitated using an Affymetrix (Woburn, Massachusetts, USA) 428 Array Scanner and ImaGene software (BioDiscovery, Los Angeles, California, USA).
Statistical analysis
Results of data obtained from multiple experiments are reported as the mean AE SEM. Significance levels were determined using Student's t-test analysis.
Results

Inhibition of the SCF-induced c-Kit phosphorylation by STI571
At first, we examined the inhibitory effect of STI571 on the SCF-induced c-Kit phosphorylation in NCI-H69 cells that were shown to express the SCF receptor, c-Kit, on the cell surface [29] . NCI-H69 cells cultured in the serum-free medium overnight were treated with varying concentrations of STI571 for 2 h, and then exposed to 50 ng/ml SCF for 15 min. Cells were harvested, and the phosphorylation of c-Kit was analyzed using the western blot technique, as described in Materials and methods. As shown in Fig. 1 , SCF induced the phosphorylation of c-Kit; STI571, at more than 1 mmol/l, clearly inhibited the SCF-induced phosphorylation in a dose-dependent manner. To confirm the equal loading of the c-Kit protein, the membrane was re-stained with an anti-c-Kit antibody. STI571 did not influence the antigen levels of c-Kit itself.
Effects of STI571 on uPA accumulation and uPA mRNA levels Next, we examined the effects of STI571 alone and the combination effects of STI571 and doxorubicin on the growth of the NCI-H69 cells and uPA expression. NCI-H69 cells were cultured with varying concentrations of STI571 with or without 2 mmol/l doxorubicin for 24 h, and then the cell density and uPA activities were measured as described in Materials and methods. Surprisingly, treatment with STI571 alone resulted in an increase in uPA activities in a dose-dependent manner, and the induction was very strong when stimulated with 20 mmol/l ( Fig. 2a ). No clear additive effects of STI571 on the doxorubicininduced uPA expression and inhibition of the cell growth were observed (data not shown). Other anticancer agents, cisplatin and etoposide, both inhibited cell growth, but did not increase the uPA accumulation in the conditioned medium (data not shown). The dose-dependent uPA induction due to STI571 was also verified by the fibrin zymography (Fig. 2b ). Northern blotting revealed the time-dependent induction of uPA mRNA, and the peak induction was observed 9 h after stimulation with STI571, as shown in Fig. 2c .
Effects of STI571 on antigen and mRNA levels of IL-8
The simultaneous induction of uPA and IL-8 was observed previously in doxorubicin-treated NCI-H69 cells, and we examined the effects of STI571 on the IL-8 expression in these cells. Reverse transcriptase-PCR revealed the induction of IL-8 after STI571 stimulation and the peak induction appeared to be 9 h, as shown in Fig. 3a . We next performed an RNase protection assay using the hCK-5 Multi-probe Template set, which contains the major chemokines, including IL-8, as described in Materials and methods, to determine other chemokines that were induced by stimulation with STI571. Among the chemokines, only IL-8 was clearly induced after the treatment (Fig. 3b) , and the other chemokines were not induced in the STI571-treated cells, although the doxorubicin-induced monocyte chemoattractant protein-1 expression was observed in the cells [21] .
To confirm that STI571 induced IL-8 expression, we measured the antigen levels of IL-8 in the conditioned medium. Treatment with STI571 for 24 h resulted in an extensive increase of IL-8 antigen levels in a dosedependent manner, and the significant induction was Inhibition of stem cell factor (SCF)-induced c-Kit phosphorylation by STI571 in NCI-H69 small cell lung cancer cells. Serum-starved NCI-H69 cells pretreated with varying concentrations of STI571 were stimulated with 50 ng/ml SCF for 15 min, and intracellular proteins were isolated and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Western blot analysis using antibodies that recognized phosphorylated and unphosphorylated c-Kit proteins was performed as described in Materials and methods.
observed when more than 5 mmol/l STI571 was used (Fig. 3c ). Next, we measured the antigen levels of PAI-1 in the same medium; however, STI571 did not affect the PAI-1 antigen levels in the cells (data not shown).
Identification of genes-induced by STI571 stimulation in NCI-H69 cells
To identify other genes whose expressions were influenced by treatment with STI571, we performed microarray analysis using the IntelliGene II Human CHIP 1, in Induction by STI571 in SCLC cells Yoshida et al. 429 (b) Dose-dependent stimulating effect of STI571 on uPA activities in NCI-H69 cells was verified using fibrin zymography. Each sample in (a) (20 ml) was applied to each lane of 7.5% sodium dodecyl sulfate-polyacrylamide gel; therefore, four samples (stimulated with 0, 5, 10 and 20 mmol/l STI571) were applied to the lanes from left to right, and the uPA standard (15 IU/ml) was applied to the right end. After electrophoresis, fibrin zymography was performed as described in Materials and methods. (c) Time course of STI571-induced uPA mRNA levels measured by northern blot analysis. Total RNA (10 mg each) was extracted from NCI-H69 cells collected at the times shown following exposure to 20 mmol/l STI571 and subjected to northern blotting, as described in Materials and methods. A b-actin cDNA probe was used as an internal control. The right lane indicates the unstimulated control for 24 h (24c). which 3893 cDNA fragments of human identified genes, including 979 kinds of cancer-related and cytokinerelated genes, were spotted on 12 separate glass plates. As shown above, the induction of IL-8 gene expression began 2 h after stimulation with STI571; we therefore treated the cells for 2 h and prepared the mRNA to identify the early genes influenced by the stimulation with 20 mmol/l STI571. A fluorescent probe was synthesized by incorporating Cy3-dUTP (untreated cells) or Cy5-dUTP (treated cells) (Amersham Life Science) using 2 mg above mRNA as a template and reverse transcriptase. Both probes were hybridized with a cDNA CHIP. As shown in Fig. 4 and Table 1 , the uPA, IL-8 and Egr-1 genes were strongly induced by treatment with STI571.
We next evaluated the mRNA levels of Egr-1 in STI571treated NCI-H69 cells. Total RNA was isolated from the stimulated NCI-H69 cells with 20 mmol/l STI571 for 2 and 9 h in serum-free medium. As shown in Fig. 5 , reverse transcriptase-PCR revealed that Egr-1 mRNA levels were clearly increased 2 h after stimulation with STI571; however, those inductions decreased 9 h after stimulation.
Phosphorylation of MAPKs in the STI571-treated cells and inhibition of STI571-induced IL-8 expression by a MAPK inhibitor
We previously described the involvement of ERK1/2 and p38 MAPK in the doxorubicin-induced uPA expression in NCI-H69 cells [30] , and the involvement of ERK1/2 was reported in dacarbazine-induced IL-8 expression [31] . We therefore examined whether MAPK pathways were involved in STI571-induced gene expression in NCI-H69 cells. NCI-H69 cells were treated with 20 mmol/l STI571 in serum-free medium for up to 8 h, and then the whole cell lysate was isolated. The western blot analysis was performed to detect the phosphorylation of each MAPK, as described in Materials and methods. Interestingly, the phosphorylation of all three MAPKs, such as ERK1/2, p38 MAPK and SAPK/JNK, was clearly induced by treatment with STI571, as shown in Fig. 6 . Next, we examined the effects of specific MAPK inhibitors on STI571-induced IL-8 induction. NCI-H69 cells were pretreated with varying concentrations of U0126, SB202190 and JNKI-1 or their inactive analogs, U0124, SB202474 and JNKI-1 NC, for 1 h and then stimulated with 20 mmol/l STI571 for 24 h. The IL-8 antigen levels in the conditioned medium were measured using the ELISA method, and the cell density was determined by the MTT assay, as described in Materials and methods. As shown in Fig. 7 , U0126 -but not its control, U0124significantly inhibited the STI571-induced IL-8 induction in a dose-dependent manner. SB202190 or JNKI-1 did not, however, inhibit the STI571-induced IL-8 induction, and those inactive analogs (SB202474 and JNKI-1 NC) also showed no effect on the STI571induced IL-8 expression ( Fig. 7) . These data suggest the involvement of ERK1/2 in the STI571-induced IL-8 expression. Microarray analysis of changes in gene expression following STI571 treatment. Total RNA was isolated from NCI-H69 cells cultured in the presence or absence of 20 mmol/l STI571 for 2 h. Then, passing through the oligo(dT) column, mRNA was purified and subjected to microarray analysis using the IntelliGene II Human CHIP 1, as described in Materials and methods. Cy3-labeled and Cy5-labeled probes were prepared with mRNA isolated from the control cells and STI571-treated cells. Blue spot, both Cy3-positive (unstimulated) and Cy5-positive (stimulated) genes; green spot, only Cy3-positive genes; light blue spot, only Cy5-positive genes; red spot, neither Cy3-positive nor Cy5-positive genes. We recognized that the blue and light blue spots were up-regulated genes induced by STI571. Egr-1, early growth response-1; IL, interleukin; uPA, urokinase-type plasminogen activator. Early growth response-1 (Egr-1) mRNA expression in NCI-H69 cells was increased by STI571 treatment. Total RNA was isolated from NCI-H69 cells treated with 20 mmol/l STI571 for 2 and 9 h. Transcriptional levels of the indicated genes were analyzed with reverse transcriptase-polymerase chain reaction using the primers described in Materials and methods. GAPDH was used as a control for total RNA.
Discussion
The zinc finger transcription factor, Egr-1, is one of a group of early response genes induced rapidly and transiently by a large number of growth factors, hormones, cytokines and injurious stimuli [32, 33] . Several reports revealed that genes encoding growth factors, such as insulin-like growth factor-II, platelet-derived growth factor A and B, and transforming growth factor-b1 were target genes of Egr-1 [34, 35] . Moreover, the induction of Egr-1 was involved in the expression of certain cytokines and chemokines. Khachigian et al. [36] reported that injury-induced endothelial Egr-1 can induce not only platelet-derived growth factor A and B, and transforming growth factor-b1, but also uPA. Giri et al. [37] reported that Egr-1 was involved in amyloid peptide-induced IL-8 in a human monocytic cell line, and the interference of Egr-1 RNA abrogated the amyloid peptide-induced IL-8 expression. The inducible Egr-1 gene expression was shown to be mediated through different subgroups of MAPK, including ERK and SAPK/JNK [33, 38] . In this experiment, STI571 induced uPA, IL-8 and Egr-1 gene expression in NCI-H69 SCLC cells, and a specific MEK1/2 inhibitor, U0126, inhibited IL-8 expression in a dose-dependent manner (Fig. 7) . Neither p38 MAPK nor SAPK/JNK inhibitor, however, showed inhibitory effects on these expressions. These data suggest that the phosphorylation of ERK1/2 and the up-regulation of the Egr-1 gene might be involved in the induction of uPA and IL-8 expression induced by STI571 in NCI-H69 cells. Our previous experiment and other reports, however, described the involvements of another transcription factor, polyomavirus enhancer A binding protein-3, in the expression of IL-8 gene induced by anticancer agents in NCI-H69 cells or other tumor cells [21, 39] . It may therefore be speculated that two cis-acting elements, Egr-1 and polyomavirus enhancer A binding protein-3 binding Time course of STI571-induced phosphorylation of mitogen-activated protein kinases (MAPKs) detected by western blot analysis. NCI-H69 cells were stimulated with 20 mmol/l STI571 in serum-free medium for up to 8 h. The intracellular fraction was subjected to western blot analysis to study the phosphorylation of MAPK (phospho-ERK1/2, phospho-p38 MAPK and phospho-SAPK/JNK) as described in Materials and methods. Equal loading was verified by immunodetecting the MAPK itself (ERK1, ERK2, p38 MAPK and c-Jun). Effects of mitogen-activated protein kinase (MAPK) inhibitors on interleukin (IL)-8 accumulation and cell density in STI571-treated NCI-H69 cells. NCI-H69 cells pretreated with varying concentrations of MAPK inhibitors or their inactive analogs for 1 h were stimulated with 20 mmol/l STI571 for 24 h. The IL-8 antigen levels in the conditioned medium and the cell density were measured with a quantitative enzyme-linked immunosorbent assay kit and MTT assay, as described in Materials and methods. Cells were pretreated with a specific MEK 1/2 inhibitor, U0126, or its inactive analog, U0124 (upper graph); with a specific p38 MAPK inhibitor, SB202190, or its inactive analog, SB202474 (middle graph); and with a specific SAPK/JNK inhibitor, JNKI-1, or its negative control, JNKI-1 NC (lower graph). Each experiment was conducted in triplicate at least twice, and the results were reproducible. Columns and circles indicate the IL-8 antigen levels and cell density, respectively. Mean AE SEM of triplicate values are shown: Ã P < 0.05, ÃÃ P < 0.01, ÃÃÃ P < 0.001 compared with control values. sites, may cooperatively act in the STI571-induced IL-8 gene expression.
We have shown here that STI571-treatment resulted in the inhibition of SCF-induced c-Kit activation in NCI-H69 cells. STI571-treatment did not, however, inhibit the phosphorylation of ERK 1/2, a potential downstream target of the c-Kit, and instead activated ERK1/2 and other MAPKs -although several reports described that STI571 inhibited the MAPK activation through the inhibition of SCF-mediated c-Kit activation in SCLC cells [12, 16] . A recent report described that BCR/ABL inhibition by STI571 enhanced the MAPK activity in CML progenitor cells [40] . There was no report, however, indicating the MAPK activation through the inhibition of SCF/c-Kit pathway by STI571. In this experiment, we used a rather high concentration of STI571 (20 mmol/l) in order to obtain reproducible results, but it is clear that IL-8, for example, was significantly induced at 5 mmol/l STI571 (Fig. 3c) , which is within the range of clinically achievable concentrations (< 10 mmol/l). Furthermore, other cytotoxic agents, such as cisplatin and etoposide, inhibited cell growth, but did not induce uPA expression. The induction of uPA, IL-8 and Egr-1 genes observed in the STI571-treated SCLC cells therefore appears not to be the result of simple nonspecific cell injury signals. In conclusion, we consider that STI571 may play a cytotoxic role on the cell growth of SCLC cells at higher concentrations (5-20 mmol/l). Such higher concentrations of STI571 may induce phosphorylation of MAPK, Egr-1 expression, and uPA and IL-8 expression, similarly in the case of injurious stimuli.
The significance of uPA and IL-8 in tumor biology is controversial and, therefore, it would not be easy to interpret the significance of STI571-induced uPA and IL-8 expression in NCI-H69 cells. UPA facilitates the potential of metastasis by degrading the extracellular matrix [41, 42] , and is thought to be one of the poor prognostic factors in human malignancies [42] . On the other hand, uPA may strengthen the anticancer effects of cytotoxic agents, especially when secreted during chemotherapy, because detached malignant cells from the matrix become more sensitive to anticancer agents [43] . IL-8 is likely to be an important regulator in cancer progression by enhancing angiogenesis and metastasis [44, 45] , but the IL-8 released from cancer cells may play a role in reducing the rate of cancer cell growth by inducing neutrophil infiltration to the cancer site [46] . Monotherapy with STI571 for SCLC patients seemed to be disappointing in its clinical trial [18] ; therefore, combination therapy with other cytotoxic agents was considered. Several reports recently described the combination effect of STI571 and other anticancer agents for the treatment of SCLC patients [47, 48] . It may, therefore, be possible to speculate that the induction of uPA and IL-8 expressions induced by STI571 treatment may strengthen the anticancer effect of cytotoxic agents when used with other anticancer agents for the treatment of SCLC patients.
